MAY 21, 2019 11:48 PM PDT

New Viable Drug Target for Prostate Cancer

WRITTEN BY: Nouran Amin

In the research community, MYC is historically known to be a difficult oncogene to target in cancer therapy. However, a recent study in the Journal of Cell Biology has found that an enzyme called PHLPP2 can serve as a potential route to target the MYC gene.

Histology slide of prostate cancer showing both benign glands and prostate carcinoma. Credit: Oncolex.org

"Now, we have a new way of getting at this old foe in cancer research," said Cold Spring Harbor Laboratory (CSHL) researcher Lloyd Trotman, who was focused on a cure for prostate cancer--one of the most prevalent cancers among men and the second leading cause of cancer death in American men.

Prostate cancer can metastasize to other parts of the body and patients with metastatic cancer have a much-reduced rate of survival than if the cancer was contained in the organ.

Now the study, co-led by Dr. Trotman and Dr. Dawid Nowak, an assistant professor at Weill Cornell and a former postdoctoral fellow at the Trotman lab, was able to examine the natural process of prostate cancer metastasis in mice and how to halt these processes by deleting the PHLPP2 enzyme.

The PHLPP2 enzyme is a critical protein in a signal pathway implicated in cell growth and survival in response to extracellular communications and signal relays. For prostate cancer, PHLPP2 cause the progression and later metastasis because it stabilizes and supports the MYC oncogene. Thus, blocking PHLPP2 can be proven as a viable drug target for the treatment of prostate cancer as it can halt the progression of cancer growth and metastasis. In addition, deleting the enzyme didn't show any symptoms of toxicity in mice or human cells.

Source: Cold Spring Harbor Laboratory

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 18, 2019
Drug Discovery
JUN 18, 2019
New Drug Therapeutic for Portal Hypertension
According to a study published in the journal of the American Gastroenterological Association, drug therapy, called sivelestat, may effectively treat life-...
JUN 18, 2019
Drug Discovery
JUN 18, 2019
Underwater Forest May Bring New Therapeutics
Microbes that produce defensive compounds have contributed to the major source of antibiotics and other therapeutics. However, due to the rise of antibioti...
JUN 18, 2019
Drug Discovery
JUN 18, 2019
How a Cancer Drug Inhibits DNA Repair in Cancer Cells
In a study published in the journal Science Translational Medicine, combing a certain cancer drug with other agents could potentially deliver a lethal blow...
JUN 18, 2019
Drug Discovery
JUN 18, 2019
Miracle Drug for Rare Genetic Disease Causes Price Concerns
A newly approved “miracle drug” called Zolgensma will be used to treat children with spinal muscular atrophy, or SMA. Unfortunately, the therap...
JUN 18, 2019
Health & Medicine
JUN 18, 2019
Remember Joe Camel? E-cigarette cartoon ads increase the chances of vaping
Do you remember the infamous "Joe Camel" advertisements for cigarettes back in the 1980s and 90s? These ads successfully got a generation of youn...
JUN 18, 2019
Drug Discovery
JUN 18, 2019
Breakthrough Synthesis Advances Potent Anti-Cancer Agent
What is now known as a "landmark in drug discovery", Harvard chemists have succeeded in synthesizing halichondrin, found naturally in sea sponges...
Loading Comments...